Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study on liver disease staging by Fibroscan® in a large group of HIVinfected patients from rural Uganda suggest unexpectedly high rates of advanced fibrosis. These results were independent from hepatitis status, initiating a discussion on the need for future liver disease monitoring in these particular patient groups.
Due to shared routes of transmission, hepatitis coinfection is common among HIV-positive patients. In Europe it is estimated that about one third of all HIVinfected patients are infected with hepatitis C and 6-8% show serological markers of chronic hepatitis B infection [1, 2] . The natural courses of hepatitis B and C are characterized by an increased fibrosis progression rate, particularly with declining CD4 + T-cell counts [3, 4] . Hepatitis-associated liver disease has become one of the leading non-AIDS causes of mortality in HIV patients in the HAART era in both Europe and North America [5, 6] . Initiation of antiviral therapy in hepatitis -coinfected patients has been associated with a significantly increased risk for hepatoxicity, warranting closer liver enzyme monitoring during treatment initiation in this particular patient subset [7] . In addition, mitochondrial toxicity, induced mainly through D-nucleosides (stavudine and didanosine), but also dyslipidaemia and insulin resistance, mostly in the context of protease inhibitor therapy, have been associated with an independent risk for development of hepatotoxicity and liver disease. This again makes regular liver enzyme controls under HIV therapy a standard recommendation in most Western European countries [8] .
In Africa little data on the development of liver disease in HIV has thus far become available and, in the setting of limited resources, not all centres which provide antiretroviral therapy regularly check for liver enzyme elevations or screen for underlying liver disease. African studies assessing the prevalence of hepatitis C monoinfection have found relatively high overall HCV prevalence rates, of around 3.0%, in subSaharan Africa, with the central African region having a higher estimated prevalence of 6%. West Africa had an estimated prevalence of 2.4% and southern and east Africa had the lowest estimated prevalence, of below 1.6% [9] . In HIV-infected subjects a slightly higher prevalence of HCV has been described, yet, this association is less evident than that observed in Western countries, reflecting the lower rate of intravenous drug use in the overall HIV patient population. This prevalence varies in studies between 3.3 and 7% [10] [11] [12] . Hepatitis B prevalence, on average, is higher than in Europe and needs to be assessed prior to HIV therapy initiation to ensure the inclusion of HIV/HBV dual-active antiretroviral agents into the antiretroviral treatment regimen. Results of a prospective cohort study of 300 Malawian adults starting ART, evaluating one-year ART outcomes according to viral hepatitis status, showed no significant differences in occurrence of hepatotoxicity, other side effects, mortality, severe morbidity, immune reconstitution or virological failure between hepatitis B and/or C coinfected patients and HIV monoinfected patients. This led to the authors' conclusion that screening for viral hepatitis B and C, and liver enzyme monitoring may not be a high priority in ART programmes in sub-Saharan Africa [10] . Few other studies have also examined liver enzyme elevations in African HIV-patients starting antiretroviral therapy and those that did again found only a
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Jürgen K Rockstroh 1 *, Lars Peters 2 , Heiner Wedemeyer low frequency of respective liver enzyme elevations, questioning the need for regular liver enzyme monitoring in a cost-sensitive environment [13] . Information on liver disease beyond liver enzyme measurements in HIV-infected individuals without underlying hepatitis coinfection in Africa has, however, so far not been studied. In the current issue of Antiviral Therapy Stabinski et al. [14] describe the first study on liver disease staging by Fibroscan ® in a large group of HIV-infected patients from rural Uganda. Surprisingly, an unexpectedly high number of more advanced liver fibrosis stages were found in the HIV-seropositive patients independent from baseline hepatitis status, suggesting additional causes of liver disease. One limitation of the study could be the missing data on HCV-coinfection rate but HCV prevalence is unlikely to be high and unlikely to account for the findings observed. In addition, patients have also not been tested for HDV coinfection. HDV is highly prevalent in some sub-Saharan countries and can cause a particularly severe course of viral hepatitis -although less than 5% of patients tested hepatitis B surface antigen positive in this study [15] . The relatively high rate of significant fibrosis in the HIV-uninfected control group (11%) again reinforces the suggestion of HIVindependent additional causes of liver fibrosis in this patient population. Heavy alcohol use was found to be one of the contributing factors, as well as the use of herbal medications. Clearly, underreporting of both could somewhat influence their true effects on the observed findings. Interestingly, in multivariate analyses the strongest risk factor for significant fibrosis was occupational fishing, which remains somewhat unclear, although occupationally acquired other hepatic infections, such as schistosomiasis, have been suggested as additional risk factors. As all risk factors combined do not explain the 50% higher increase in liver fibrosis in HIV, other causes in the context of HIV also need to be ruled out. The significantly higher rate of positive schistosoma antibodies as well as a higher proportion of subjects reporting current alcohol use in the HIV patient group may, however, contribute to the differences observed between the two groups. In addition, the question arises of whether liver disease per se may take a more unfavourable course in HIV, particularly with declining CD4 + T-cell counts as the immune system becomes unable to deal with the underlying pathogen, leading to liver disease. How far mitochondrial toxicity caused by D-drugs (stavudine and didanosine) also plays a role is not confirmed by this investigation and would need to be clarified. Overall however, HAART use was associated with a 40% protective effect, clearly emphasising that advanced immunodeficiency appears, independently, to be a contributing factor to fibrosis development. As data from rural Uganda cannot be extrapolated to all African regions, clearly more research in different areas of Africa on the prevalence of liver fibrosis in HIV-positive as well as HIV-negative subjects is urgently needed. In addition, the question arises of how far the non-invasive tool Fibroscan ® needs to be validated in African patients because most investigations have been carried out in Caucasian patient populations from Europe or North America. Validation would also need to occur with regard to other chronic liver diseases causing fibrosis, such as schistosomiasis, as most investigations so far have only focused on fibrosis evaluation in chronic hepatitis C or B.
The present study emphasises the need for additional investigations to better define potential mechanisms leading to fibrosis progression and the development of liver cirrhosis in HIV infection. In this context, several recent findings are of interest and should be considered, including Vitamin D serum levels, the effects of GB virus C-coinfection altering intrahepatic T-cell signalling, the direct effects of HIV on hepatocyte apoptosis and hepatic stellate cells or the role of the interleukin-28B genotype [16] [17] [18] [19] . In this paper, Stabinski et al. [14] add interesting additional potential players to the orchestra of pro-fibrotic factors, with herbal medication use and occupational fishing deserving of further investigation. In any case, the observed high prevalence of liver fibrosis in rural Rakai strongly emphasises the need for further studies on liver fibrosis in African patients because many new questions emerge from the findings of this study, which only new research efforts can provide adequate answers to.
